Availability: | |
---|---|
Cloperastine hydrochloride CAS 14984-68-0 Product Information
CAS No | 14984-68-0 |
Product Name | 4-Chlorobenzhydrol |
Synonyms | 1-(2-((p-chloro-alpha-phenylbenzyl)oxy)ethyl)-piperidinhydrochloride;1-(2-(p-cloro-alpha-fenilbenzilossi)etil)piperidinacloridrato;2-piperidinoethylp-chlorobenzhydryletherhydrochloride;cloperastinacloridrato;ht11;hustazol;4-CHLOROBENZHYDRYL2-[1-PIPERIDYL]-ETHYLETHERHYDROCHLORIDE;CHLOPERASTINEHYDROCHLORIDE |
Free Sample | Available |
Molecular Formula | C20H25Cl2NO |
Molecular Weight | 366.32 |
Purity | 99% |
Free Shipping | YES |
Cloperastine hydrochloride CAS 14984-68-0 Product Information
CAS No | 14984-68-0 |
Product Name | 4-Chlorobenzhydrol |
Synonyms | 1-(2-((p-chloro-alpha-phenylbenzyl)oxy)ethyl)-piperidinhydrochloride;1-(2-(p-cloro-alpha-fenilbenzilossi)etil)piperidinacloridrato;2-piperidinoethylp-chlorobenzhydryletherhydrochloride;cloperastinacloridrato;ht11;hustazol;4-CHLOROBENZHYDRYL2-[1-PIPERIDYL]-ETHYLETHERHYDROCHLORIDE;CHLOPERASTINEHYDROCHLORIDE |
Free Sample | Available |
Molecular Formula | C20H25Cl2NO |
Molecular Weight | 366.32 |
Purity | 99% |
Free Shipping | YES |
Cloperastine hydrochloride CAS 14984-68-0 Chemical Properties
Melting point | 147.9° |
Storage conditions | Inert atmosphere,Room Temperature |
Solubility | Soluble in DMSO (a little), methanol (a little) |
Acidity coefficient (pKa) | 13.34±0.20(Predicted) |
Color | White to off-white |
Cloperastine hydrochloride CAS 14984-68-0 Chemical Properties
Melting point | 147.9° |
Storage conditions | Inert atmosphere,Room Temperature |
Solubility | Soluble in DMSO (a little), methanol (a little) |
Acidity coefficient (pKa) | 13.34±0.20(Predicted) |
Color | White to off-white |
Cloperastine hydrochloride CAS 14984-68-0 Chemical Properties,Uses,Production
Biological Activity
Cloperastine hydrochloride inhibits hERG K+ current with an IC50 of 27 nM in a concentration-dependent manner.
Target
27 nM (K + currents)
In Vitro Studies
Cloperastine inhibits the hERG K + currents in a concentrationdependent manner with an IC 50 value of 27 nM.Among the antitussive agents, Cloperastine, which possesses antitussive and antiedemic activity, also relaxes the bronchial musculature. Cloperastine is a drug with a central antitussive effect, and is also endowed with an antihistaminic and papaverine-like activity similar to codeine but without its narcotic effects.
In Vivo Studies
In the anesthetized guinea pigs, Cloperastine at a therapeutic dose of 1 mg/kg prolonged the QT interval and monophasic action potential (MAP) duration without affecting PR interval or QRS width. Cloperastine hydrochloride shows relatively low acute toxicity when administered by the intraperitoneal route in rats and mice, and shows minor toxicity by the oral route when administered as Cloperastine fendizoate, the LD 50 in rats and mice for the two administration routes exceeds 1000 and 2000 mg/kg, respectively.
Cloperastine hydrochloride CAS 14984-68-0 Chemical Properties,Uses,Production
Biological Activity
Cloperastine hydrochloride inhibits hERG K+ current with an IC50 of 27 nM in a concentration-dependent manner.
Target
27 nM (K + currents)
In Vitro Studies
Cloperastine inhibits the hERG K + currents in a concentrationdependent manner with an IC 50 value of 27 nM.Among the antitussive agents, Cloperastine, which possesses antitussive and antiedemic activity, also relaxes the bronchial musculature. Cloperastine is a drug with a central antitussive effect, and is also endowed with an antihistaminic and papaverine-like activity similar to codeine but without its narcotic effects.
In Vivo Studies
In the anesthetized guinea pigs, Cloperastine at a therapeutic dose of 1 mg/kg prolonged the QT interval and monophasic action potential (MAP) duration without affecting PR interval or QRS width. Cloperastine hydrochloride shows relatively low acute toxicity when administered by the intraperitoneal route in rats and mice, and shows minor toxicity by the oral route when administered as Cloperastine fendizoate, the LD 50 in rats and mice for the two administration routes exceeds 1000 and 2000 mg/kg, respectively.